AJM Online
Clinical communication to the Editor
Severe Hepatic Injury Caused by Orlistat

https://doi.org/10.1016/j.amjmed.2005.12.003Get rights and content

References (4)

There are more references available in the full text version of this article.

Cited by (17)

  • Susceptible genetic polymorphisms and their association with adverse effects of orlistat therapy

    2021, Obesity Medicine
    Citation Excerpt :

    Morris et al., 2012). A 35-year-old woman who was moderately obese with sub-acute hepatic failure undergone liver transplantation was treated with orlistat 120 mg/day (Umemura et al., 2006). After three weeks, a usual laboratory check demonstrated severely impaired liver function.

  • Antiobesity effect of ethanolic extract of Ramulus mori in differentiated 3T3-L1 adipocytes and high-fat diet-induced obese mice

    2020, Journal of Ethnopharmacology
    Citation Excerpt :

    In the case of GOT, the orlistat-treated group showed a significantly high level, and the GPT levels of the model group and the orlistat-treated group were significantly higher than those in the ERM-treated groups (Table 2). The results were consistent with the previously reported side effect of orlistat stating that orlistat treatment is associated with acute liver injury (Douglas et al., 2013; Umemura et al., 2006). There was no significant change in the concentrations of GOT and GPT in the ERM-treated groups compared with the same parameters in the negative control group, which suggests that ERM may not be toxic to the experimental animals at the concentrations used in this study.

  • Bariatric embolization: a new and effective option for the obese patient?

    2017, Expert Review of Gastroenterology and Hepatology
View all citing articles on Scopus
View full text